DPP4 and diabetes mellitus: In diabetes care, pharmacogenomics has shown promise in tailoring treatments involving commonly prescribed agents such as metformin, sulfonylureas, thiazolidinediones, and dipeptidyl peptidase-4 (DPP-4) inhibitors, among others [5].